Latest News

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.
FDA OKs Zanidatamab Injection for Metastatic HER2+ Biliary Tract Cancer

November 21st 2024

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?
Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?

November 12th 2024

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.
Approaching End-of-Life Discussions With Directness and Compassion

October 30th 2024

PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications
PDUFA Dates Pushed for Sotorasib/Obeticholic Acid in GI Indications

October 22nd 2024

Omitting bolus 5-fluouracil in chemotherapy-based treatment for patients with gastrointestinal cancers may reduce adverse effects and healthcare costs.
5-FU Bolus Omission May Reduce Toxicity, Maintain Efficacy in GI Cancers

October 14th 2024